Literature DB >> 16354543

Therapeutic efficacy of intraventricular cyclosporine A and methylprednisolone on a global cerebral ischemia model in rats.

Gökhan Akdemir1, M Fikret Ergüngör, Mustafa Sezer, Levent Albayrak, Ergün Dağlioğlu, Kamer Kilinç.   

Abstract

OBJECTIVE: Cyclosporine A (CsA) with its immunosuppressive actions and methylprednisolone (MP) as a free radical scavenger were suggested together to alleviate neural tissue damage after an ischemic insult. The aim of this study was to investigate neuroprotective properties of CsA and MP in a global cerebral ischemia model.
METHODS: Twenty-eight male Sprague-Dawley rats were divided randomly into four separate groups: CsA, MP, sham and control. Global cerebral ischemia was performed with the four-vessel occlusion model. After 30 minutes of ischemia, reperfusion was started with concomitant intraventricular administration of saline, MP (20 mg/kg) and CsA (10 mg/kg) into the lateral ventricle. Lipid peroxidation levels were measured from all experimental groups. Rats subjected to global cerebral ischemia exhibited a significant increase in cerebral lipid peroxide levels 6 hours after the onset of reperfusion. Both CsA and MP treatment significantly attenuated the degree of lipid peroxidation in cerebral tissues (p<0.05). Histopathological examinations of the CA1 sector of the hippocampus verified the neuroprotective properties of MP and CsA.
CONCLUSIONS: The results suggested the neuroprotective properties of both agents, emphasizing more potent protection against ischemia by CsA. It was proposed that CsA could have exerted this effect with the blockage of mitochondrial permeability transition (MPT) pores, which are also critical if the necrotic and apoptotic cascades of the cell are considered. MP is judged to be neuroprotective, particularly in terms of its effects on lipid peroxidation. In conclusion, CsA and MP are ascertained to be neuroprotective agents as long as they cross the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16354543     DOI: 10.1179/016164105X63610

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  6 in total

1.  In vivo opening of the mitochondrial permeability transition pore in a rat model of ventricular fibrillation and closed-chest resuscitation.

Authors:  Iyad M Ayoub; Jeejabai Radhakrishnan; Raúl J Gazmuri
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Intrathecal corticoids in permanent focal cerebral ischemia in rats. Part I: a new therapeutic approach in the acute phase.

Authors:  Sophia L Goericke; Tobias Engelhorn; Michael Forsting; Ulrich Speck; Stefan Maderwald; Mark E Ladd; Arnd Doerfler
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

Review 3.  Systemic delivery of umbilical cord blood cells for stroke therapy: a review.

Authors:  Guolong Yu; Cesar V Borlongan; Christine E Stahl; David C Hess; Yali Ou; Yuji Kaneko; Seong Jin Yu; Tianlun Yang; Li Fang; Xiumei Xie
Journal:  Restor Neurol Neurosci       Date:  2009       Impact factor: 2.406

4.  Attenuation of circulatory shock and cerebral ischemia injury in heat stroke by combination treatment with dexamethasone and hydroxyethyl starch.

Authors:  Tsai-Hsiu Yang; Mei-Fen Shih; Yi-Szu Wen; Wen-Yueh Ho; Kuen-Lin Leu; Mei-Ying Wang; Chia-Chyuan Liu
Journal:  Exp Transl Stroke Med       Date:  2010-10-11

5.  Dexamethasone improves heat stroke-induced multiorgan dysfunction and damage in rats.

Authors:  Chia-Chyuan Liu; Mei-Fen Shih; Yi-Szu Wen; Ying-Hsiu Lai; Tsai-Hsiu Yang
Journal:  Int J Mol Sci       Date:  2014-11-18       Impact factor: 5.923

6.  Reframing the Biological Basis of Neuroprotection Using Functional Genomics: Differentially Weighted, Time-Dependent Multifactor Pathogenesis of Human Ischemic Brain Damage.

Authors:  William A Kofke; Yue Ren; John G Augoustides; Hongzhe Li; Katherine Nathanson; Robert Siman; Qing Cheng Meng; Weiming Bu; Sukanya Yandrawatthana; Guy Kositratna; Cecilia Kim; Joseph E Bavaria
Journal:  Front Neurol       Date:  2018-06-26       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.